NewAmsterdam Pharma’s cholesteryl ester transfer protein (CETP) inhibitor, obicetrapib, significantly reduced plasma p-tau217 levels, a key Alzheimer’s disease biomarker, in a prespecified analysis of the BROADWAY cardiovascular outcomes trial. In the full analysis set (n=1515), obicetrapib lowered p-tau217 by 2.99% (p=0.0019) compared to placebo. Among ApoE4 carriers (n=367), a group at higher risk for both cardiovascular disease and Alzheimer’s, the reduction was 5.74% (p=0.0215). Notably, the highest-risk E4/E4 homozygotes (n=29) experienced a 20.48% reduction in p-tau217 (p=0.010). Other Alzheimer ’ ”s-related biomarkers, including NFL, GFAP, p-tau181, and the Aβ42/40 ratio, also showed favorable, though not always statistically significant, trends.
This announcement positions obicetrapib as a potential multi-disease intervention, targeting both cardiovascular and neurodegenerative risk. NewAmsterdam is aiming to expand the drug’s market beyond its initial cardiovascular focus. While the BROADWAY trial primarily measured LDL-C reduction in patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), the embedded Alzheimer’s analysis allows the company to explore a much larger preventive market. This strategy hinges on validating p-tau217 as a surrogate endpoint for Alzheimer’s disease progression – a critical factor for regulatory acceptance of any future preventive indication.
This approach raises several key questions. First, will the observed biomarker changes translate into clinically meaningful cognitive benefits? The company’s earlier Phase 2a trial in ApoE4 carriers demonstrated reductions in brain cholesterol metabolites, but the BROADWAY analysis did not include cognitive assessments. Second, how will regulators view the safety data for obicetrapib in the context of Alzheimer’s prevention? While the drug appears well-tolerated in cardiovascular trials, its long-term safety profile in a potentially healthy, pre-dementia population remains to be established. Finally, how will payers assess the cost-effectiveness of a preventive treatment for a disease that typically manifests decades later?
The impact of these findings could ripple across multiple stakeholder groups. If obicetrapib demonstrates a clinical benefit in Alzheimer’s prevention, it could shift the paradigm for clinical trial design and patient recruitment. Trials might enroll earlier-stage, asymptomatic individuals based on genetic risk rather than existing cognitive impairment. This would significantly expand the pool of eligible participants, but also introduce challenges in managing trial duration and endpoint assessment. It could also create new competition between cardiovascular and neurology specialists for patients.
NewAmsterdam now faces the critical decision of how to translate these biomarker findings into a viable clinical development program. The company will need to engage with regulators to design a definitive trial that can conclusively demonstrate a clinical benefit. Success hinges on the FDA’s willingness to accept biomarker data as a sufficient basis for approval in the absence of clear cognitive improvements. This presents a high-stakes gamble for the company: a successful outcome could redefine Alzheimer’s prevention, but failure could confine obicetrapib to the more crowded cardiovascular market. Watch for NewAmsterdam’s discussions with regulatory authorities, the design of future Alzheimer ””s-focused trials, and the evolving regulatory landscape for preventive interventions in neurodegenerative disease.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
